IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 16, 2016 / Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (NASDAQ: ALXN) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at brian@lundinlawpc.com.

On November 9, 2016, Alexion announced that is investigating accusations of improper sales practices of its top drug, Soliris, which is estimated to account for 92% of the Company’s sales for 2016. The Company retained outside counsel and announced its decision to delay its third-quarter financial report.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 449197